Market Trends and Forecast: Point of Care Molecular Diagnostics for Cancer Diagnosis
Point of Care Molecular Diagnostics Market
Overview
The global point-of-care
molecular diagnostics market size is projected to reach USD 4.1 billion
by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2%. This growth is
attributed to the increasing incidence of infectious diseases, rising awareness
among patients and healthcare professionals, technological advancements in
molecular diagnostics, and increasing adoption of point-of-care testing.
Additionally, factors such as the growing geriatric population and rising
demand for personalized medicine are expected to drive the market growth.
However, high cost associated with molecular diagnostics and the lack of
reimbursement policies in some countries are likely to hamper the growth of the
market.
Point of Care Molecular Diagnostics Market
Trends and Drivers
The Point of Care Molecular
Diagnostics market is expected to witness significant growth over the forecast
period. This growth can be attributed to the increasing prevalence of infectious
diseases and rising demand for quick diagnosis. Growing awareness regarding the
importance of early diagnosis of diseases is also driving the growth of the
market. In addition, increasing investment in molecular diagnostics by
governments in developing countries and rising healthcare expenditure are
expected to further drive the growth of the market. Moreover, the emergence of
advanced technologies such as multiplex and miniaturized assays is likely to
propel the growth of the market. Furthermore, increasing research and
development activities and the introduction of novel products are expected to
provide significant opportunities for the growth of the market.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=143524127
Regional Point of Care Molecular Diagnostics
Market Analysis
The regional point of care
molecular diagnostics market is segmented into North America, Europe, Asia
Pacific and the Rest of the World. North America dominates the market owing to
the presence of a large number of players, technological advancements, and the
presence of a well-established healthcare sector. Europe is the second largest
market due to the presence of sophisticated healthcare infrastructure and
increasing adoption of POC molecular diagnostics. Asia Pacific is expected to
witness significant growth due to the presence of huge population, increasing
awareness of POC molecular diagnostics, and rising government investments in
the healthcare sector. The Rest of the World is expected to witness moderate
growth due to the presence of developing healthcare infrastructure and the
increasing focus of market players on emerging economies.
Major Players in the Point of Care Molecular
Diagnostics Market
The major players in this market
are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland),
bioMérieux SA (France), Danaher Corporation (US), Quidel Corporation (US),
QIAGEN N.V. (Netherlands), Co-Diagnostics, Inc. (US), Biocartis NV (Belgium),
Meridian Bioscience, Inc. (US), Thermo Fisher Scientific, Inc. (US), Lucira
Health, Inc. (US), Cue Health (US), OpGen, Inc. (US), Binx Health, Inc. (US),
Molbio Diagnostics Pct. Ltd. (India), Genomadix (Canada), Visby Medical, Inc.
(US), QuikPath PTE Ltd. (Singapore), MD-Bio (US), QuantuMDx Group Ltd. (UK),
Aidian Oy (Finland), and GeneSTAT Molecular Diagnostics, LLC (US).
Impact of COVID-19 on the Point of Care
Molecular Diagnostics Market
The outbreak of the coronavirus
pandemic has had a major impact on the point of care molecular diagnostics
market. The demand for point of care molecular diagnostics has increased
drastically due to the need for rapid diagnosis and testing of COVID-19.
Governments and healthcare organizations across the world have been taking
various initiatives to increase the availability of point of care molecular
diagnostics tests, in order to enable early diagnosis and treatment of the
disease. Furthermore, the development of various molecular diagnostics tests
for COVID-19 has further driven the demand for point of care molecular
diagnostics. However, the pandemic has also caused disruption in the supply
chain of various point of care molecular diagnostics products, due to the
restrictions imposed by governments in order to contain the spread of the
virus. This has hindered the growth of the point of care molecular diagnostics
market.
Challenges and Opportunities in the Point of
Care Molecular Diagnostics Market
The point of care (POC) molecular
diagnostics market is a rapidly growing market that provides more accurate and
timely diagnosis of diseases. However, there are a number of challenges and
opportunities that providers and patients face when considering POC molecular
diagnostics.
Challenges:
·
Cost: The cost of POC molecular diagnostics
tests is typically much higher than standard laboratory tests, making them less
accessible for many patients.
·
Availability: POC molecular diagnostics tests
are not available in all locations, making them difficult to access for
patients in certain areas.
·
Regulatory Hurdles: Regulatory hurdles, such as
the need for premarket approval from the FDA, can be difficult and time
consuming for manufacturers of POC molecular diagnostics tests.
·
Training and Education: There is a need for
training and education for healthcare providers regarding the use of POC
molecular diagnostics tests.
Opportunities:
·
Increase in Demand: The demand for POC molecular
diagnostics tests is expected to increase as the technology becomes more
popular and accessible.
·
Unmet Needs: There are a number of unmet needs
in the POC molecular diagnostics market, providing opportunities for new
products and services.
·
Technological Advances: Technological advances,
such as the development of more accurate tests, are opening up new
opportunities for POC molecular diagnostics.
·
Collaboration: Collaboration between healthcare
providers, manufacturers, and regulatory bodies can help to facilitate the
development and adoption of POC molecular diagnostics tests.
Conclusion: What is the Future of the Point
of Care Molecular Diagnostics Market?
The future of the point of care
molecular diagnostics market is expected to be strong in the years to come. The
increasing demand for accurate, rapid and cost-effective diagnostic tests is
driving the growth of the market. Furthermore, the rising prevalence of
infectious diseases and chronic conditions is expected to fuel the demand for
point of care molecular diagnostics. With the advent of new technological
advancements, such as digital PCR and CRISPR-based diagnostics, the market is
likely to witness significant growth in the near future. Additionally,
strategic collaborations between market players and rising investments in R&D
are expected to further accelerate the growth of the market.
Related Content Source:
https://www.marketsandmarkets.com/PressReleases/point-of-care-molecular-diagnostic.asp
https://www.marketsandmarkets.com/ResearchInsight/point-of-care-molecular-diagnostic-market.asp
Comments
Post a Comment